

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P O Box 1450 Alexandria, Virginsa 22313-1450 www.msplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/927,914	08/10/2001	Timothy P. Tully	21RE-137270	5180
68850 7550 09/10/2010 DON J. PELTO Sheppard, Mullin, Richter & Hampton LLP			EXAMINER	
			CHONG, YONG SOO	
1300 I STREET, NW 11TH FLOOR EAST			ART UNIT	PAPER NUMBER
WASHINGTON, DC 20005			1627	
			MAIL DATE	DELIVERY MODE
			09/10/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Examiner-Initiated Interview Summary	09/927,914	TULLY ET AL.				
Examiner-induced interview duminary	Examiner	Art Unit				
	Yong S. Chong	1627				
All Participants:	Status of Application:					
(1) Yong S. Chong.	(3)					
(2) Mr. Don Pelto.	(4)					
Date of Interview: 9 September 2010	Time: 3:15 pm					
Type of Interview: ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative) Exhibit Shown or Demonstrated: ☐ Yes ☐ No If Yes, provide a brief description: ☐ No						
Part I.						
Rejection(s) discussed:						
Claims discussed: all pending						
Prior art documents discussed:						
Part II. SUBSTANCE OF INTERVIEW DESCRIBING THE GENE See Continuation Sheet	RAL NATURE OF WHAT WAS	B DISCUSSED:				
Part III.						
It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability. It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.						
/Yong S. Chong/ Primary Examiner, Art Unit 1627	Applicant/Applicant's Representat	ive Signature – if appropriate)				

Application No. 09/927,914

Continuation of Substance of Interview including description of the general nature of what was discussed: Upon the conclusion of the pre-appeal conference, several minor issues needs to be addressed before the case is sent to the Board. In particular, Applicant was notified of an issue with claim 8, which recites that all PDE4 inhibitors induce CREB-dependent gene expression. This may be in error as the specification appears to only state that only the augmenting agent, modulators of protein kinases and protein phosphatases mediate CREB-dependent gene expression (last paragraph of page 18). Applicant was asked if it is known in the art that all PDE4 inhibitors induce CREB-dependent gene expression. If this is not the case, Applicant is encouraged to cancel claim 8 in order to simplify all issues to the Board and to expedite prosecution. There are other minor claim amendments that are necessary that was communicated to the Applicant. Examiner will enter the necessary claim amendments after final if the Applicant agrees to make these changes. Examiner awaits an answer.